Great article by Dr. Michael Manning, M.D.
What are the treatment options for documented allergic disease?  If 
you do not know what the facts are, the answers can be very confusing.  
When treating hay fever or allergic rhinitis, asthma and sometimes 
eczema, there are three main categories of treatment options.  First, 
one should always try and avoid any offending allergy triggers.  Second,
 there are a variety of medications that may be effective.  Lastly, 
allergen immunotherapy, also known as allergy shots, can be instituted 
if the first two options are ineffective.  So where does allergy drops 
fit in, if at all?
Allergy drops, or more properly known as sublingual immunotherapy 
(SLIT), are a form of allergen immunotherapy developed in Europe.  The 
purpose of sublingual immunotherapy is the same as traditional 
subcutaneous immunotherapy (SCIT) or allergy shots.  Subcutaneous 
immunotherapy works by readjusting or rebalancing the immune system so 
that it stops reacting to allergy triggers.
 When someone is allergic his or her immune system has made an allergic 
antibody to a pollen, dander or mold.  This antibody, when exposed to 
the allergen, starts a reaction that ends with the symptoms of hay fever
 or asthma, such as runny nose, nasal congestion, and watery itchy eyes,
 coughing or wheezing.  This is actually an over-active immune system.  
Therefore the goal of subcutaneous immunotherapy is to calm down this 
over-active immune response.  For allergy shots to work, the patient 
needs to be allergic to substances that are appropriate for allergen 
immunotherapy.  The allergy shot serum should include the allergens the 
patient is allergic to and not include the ones that they are not 
reactive to.  This means the serum should be customized to each 
patient.  Also, the serum must be mixed correctly in that certain 
allergens cannot be put together in the same serum as they degrade each 
other.  This process takes time but is the best long-term solution to 
control allergies.
 Sublingual immunotherapy has the same biological effects as subcutaneous
 immunotherapy.  This was refined in Europe and has shown excellent 
benefit when used in the appropriate patient.  Sublingual immunotherapy 
works best in those individuals that are not allergic to a lot of 
different allergens.  Currently there are no FDA approved sublingual 
extracts or serum in the United States. This also means that insurance 
companies will not cover sublingual immunotherapy. Studies to obtain FDA
 approval are ongoing.  When FDA approval is obtained, sublingual 
immunotherapy will be an appropriate treatment option for the control of
 allergic rhinitis or hay fever and asthma.
 So what is the problem?  Unfortunately, there is a lot of misinformation
 about sublingual immunotherapy.  Many practitioners advertise drops as 
being safe with no potential for systemic or severe reactions like can 
be seen with subcutaneous immunotherapy.  This is not true.  Systemic 
reactions can occur with sublingual treatment therefore care must be 
taken when sublingual immunotherapy is started and advanced. Local 
reactions in the mouth, throat and stomach also occur. Sublingual 
immunotherapy, when it obtains FDA approval, needs to be performed under
 proper supervision by a physician specifically trained in allergy and 
immunology.  Also, like subcutaneous immunotherapy, sublingual extracts 
should be customized for the patient.  There is no one drop fits all.
 When sublingual immunotherapy receives FDA approval, it will be an added
 treatment option for patients with allergic rhinitis or asthma.  If 
avoidance measures and medications do not adequately control symptoms 
and the patient is only allergic to a few allergens, then sublingual 
immunotherapy may be the next step in treatment.  In patients who fail 
to respond to sublingual immunotherapy or who react to a multitude of 
allergens, then traditional subcutaneous immunotherapy would be the best
 option.  Until that point, make sure your treatment program is 
appropriate and backed by scientific study.
 
No comments:
Post a Comment